Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis
- 1 November 2017
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 85, 146-154
- https://doi.org/10.1016/j.ejca.2017.08.018
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Palbociclib and Letrozole in Advanced Breast CancerThe New England Journal of Medicine, 2016
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology GuidelineJournal of Clinical Oncology, 2016
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trialAnnals of Oncology, 2016
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyThe Lancet Oncology, 2015
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2Annals of Oncology, 2014
- Cost-Effectiveness of Lapatinib plus Letrozole in her2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer in CanadaCurrent Oncology, 2013
- Guidelines for Health Technologies: Specific Guidance for Oncology Products in CanadaValue in Health, 2012
- Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited SettingPLOS ONE, 2012
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- Health state utilities for metastatic breast cancerBritish Journal of Cancer, 2006